Literature DB >> 26202230

Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques.

Kenny L Lin1, Nancy A Twenhafel1, John H Connor2, Kathleen A Cashman1, Joshua D Shamblin1, Ginger C Donnelly1, Heather L Esham1, Carly B Wlazlowski1, Joshua C Johnson3, Anna N Honko3, Miriam A Botto1, Judy Yen2, Lisa E Hensley3, Arthur J Goff4.   

Abstract

UNLABELLED: Marburg virus (MARV) infection is a lethal hemorrhagic fever for which no licensed vaccines or therapeutics are available. Development of appropriate medical countermeasures requires a thorough understanding of the interaction between the host and the pathogen and the resulting disease course. In this study, 15 rhesus macaques were sequentially sacrificed following aerosol exposure to the MARV variant Angola, with longitudinal changes in physiology, immunology, and histopathology used to assess disease progression. Immunohistochemical evidence of infection and resulting histopathological changes were identified as early as day 3 postexposure (p.e.). The appearance of fever in infected animals coincided with the detection of serum viremia and plasma viral genomes on day 4 p.e. High (>10(7) PFU/ml) viral loads were detected in all major organs (lung, liver, spleen, kidney, brain, etc.) beginning day 6 p.e. Clinical pathology findings included coagulopathy, leukocytosis, and profound liver destruction as indicated by elevated liver transaminases, azotemia, and hypoalbuminemia. Altered cytokine expression in response to infection included early increases in Th2 cytokines such as interleukin 10 (IL-10) and IL-5 and late-stage increases in Th1 cytokines such as IL-2, IL-15, and granulocyte-macrophage colony-stimulating factor (GM-CSF). This study provides a longitudinal examination of clinical disease of aerosol MARV Angola infection in the rhesus macaque model. IMPORTANCE: In this study, we carefully analyzed the timeline of Marburg virus infection in nonhuman primates in order to provide a well-characterized model of disease progression following aerosol exposure.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26202230      PMCID: PMC4577920          DOI: 10.1128/JVI.01147-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Evaluation of perceived threat differences posed by filovirus variants.

Authors:  Jens H Kuhn; Lori E Dodd; Victoria Wahl-Jensen; Sheli R Radoshitzky; Sina Bavari; Peter B Jahrling
Journal:  Biosecur Bioterror       Date:  2011-11-09

2.  Clinical aspects of Marburg hemorrhagic fever.

Authors:  Masfique Mehedi; Allison Groseth; Heinz Feldmann; Hideki Ebihara
Journal:  Future Virol       Date:  2011-09       Impact factor: 1.831

3.  Marburg hemorrhagic fever associated with multiple genetic lineages of virus.

Authors:  Daniel G Bausch; Stuart T Nichol; Jean Jacques Muyembe-Tamfum; Matthias Borchert; Pierre E Rollin; Hilde Sleurs; Patricia Campbell; Florimund K Tshioko; Catherine Roth; Robert Colebunders; Patricia Pirard; Simon Mardel; Loku A Olinda; Hervé Zeller; Antoine Tshomba; Amayo Kulidri; Modeste L Libande; Sabue Mulangu; Pierre Formenty; Thomas Grein; Herwig Leirs; Leo Braack; Tom Ksiazek; Sherif Zaki; Michael D Bowen; Sheilagh B Smit; Patricia A Leman; Felicity J Burt; Alan Kemp; Robert Swanepoel
Journal:  N Engl J Med       Date:  2006-08-31       Impact factor: 91.245

Review 4.  How Ebola and Marburg viruses battle the immune system.

Authors:  Mansour Mohamadzadeh; Lieping Chen; Alan L Schmaljohn
Journal:  Nat Rev Immunol       Date:  2007-07       Impact factor: 53.106

Review 5.  Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies.

Authors:  Jens H Kuhn
Journal:  Arch Virol Suppl       Date:  2008

6.  Marburg agent disease: in monkeys.

Authors:  D I Simpson
Journal:  Trans R Soc Trop Med Hyg       Date:  1969       Impact factor: 2.184

Review 7.  Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions.

Authors:  Daniel G Bausch; A G Sprecher; Benjamin Jeffs; Paul Boumandouki
Journal:  Antiviral Res       Date:  2008-02-26       Impact factor: 5.970

Review 8.  Outbreak of Marburg hemorrhagic fever in Angola: a review of the history of the disease and its biological aspects.

Authors:  B Lee Ligon
Journal:  Semin Pediatr Infect Dis       Date:  2005-07

9.  Transmission of Ebola virus from pigs to non-human primates.

Authors:  Hana M Weingartl; Carissa Embury-Hyatt; Charles Nfon; Anders Leung; Greg Smith; Gary Kobinger
Journal:  Sci Rep       Date:  2012-11-15       Impact factor: 4.379

10.  Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2.

Authors:  Thomas W Geisbert; Kathleen M Daddario-DiCaprio; Joan B Geisbert; Howard A Young; Pierre Formenty; Elizabeth A Fritz; Tom Larsen; Lisa E Hensley
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

View more
  14 in total

1.  Natural History and Pathogenesis of Wild-Type Marburg Virus Infection in STAT2 Knockout Hamsters.

Authors:  Colm Atkins; Jinxin Miao; Birte Kalveram; Terry Juelich; Jennifer K Smith; David Perez; Lihong Zhang; Jonna L B Westover; Arnaud J Van Wettere; Brian B Gowen; Zhongde Wang; Alexander N Freiberg
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

Review 2.  Filovirus Strategies to Escape Antiviral Responses.

Authors:  Judith Olejnik; Adam J Hume; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler; Elke Mühlberger
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

3.  Transcriptional Profiling of the Immune Response to Marburg Virus Infection.

Authors:  John H Connor; Judy Yen; Ignacio S Caballero; Sara Garamszegi; Shikha Malhotra; Kenny Lin; Lisa Hensley; Arthur J Goff
Journal:  J Virol       Date:  2015-07-22       Impact factor: 5.103

Review 4.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

5.  Dimerization Controls Marburg Virus VP24-dependent Modulation of Host Antioxidative Stress Responses.

Authors:  Britney Johnson; Jing Li; Jagat Adhikari; Megan R Edwards; Hao Zhang; Toni Schwarz; Daisy W Leung; Christopher F Basler; Michael L Gross; Gaya K Amarasinghe
Journal:  J Mol Biol       Date:  2016-08-04       Impact factor: 5.469

Review 6.  The Role of Cytokines and Chemokines in Filovirus Infection.

Authors:  Sandra L Bixler; Arthur J Goff
Journal:  Viruses       Date:  2015-10-23       Impact factor: 5.048

7.  A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever.

Authors:  Andrea Marzi; Logan Banadyga; Elaine Haddock; Tina Thomas; Kui Shen; Eva J Horne; Dana P Scott; Heinz Feldmann; Hideki Ebihara
Journal:  Sci Rep       Date:  2016-12-15       Impact factor: 4.379

8.  A Four-Biomarker Blood Signature Discriminates Systemic Inflammation Due to Viral Infection Versus Other Etiologies.

Authors:  D L Sampson; B A Fox; T D Yager; S Bhide; S Cermelli; L C McHugh; T A Seldon; R A Brandon; E Sullivan; J J Zimmerman; M Noursadeghi; R B Brandon
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

9.  Dose Response of MARV/Angola Infection in Cynomolgus Macaques following IM or Aerosol Exposure.

Authors:  Sara C Johnston; Kenny L Lin; Nancy A Twenhafel; Jo Lynne W Raymond; Joshua D Shamblin; Suzanne E Wollen; Carly B Wlazlowski; Eric R Wilkinson; Miriam A Botto; Arthur J Goff
Journal:  PLoS One       Date:  2015-09-28       Impact factor: 3.240

10.  Natural History of Aerosol Exposure with Marburg Virus in Rhesus Macaques.

Authors:  Evan C Ewers; William D Pratt; Nancy A Twenhafel; Joshua Shamblin; Ginger Donnelly; Heather Esham; Carly Wlazlowski; Joshua C Johnson; Miriam Botto; Lisa E Hensley; Arthur J Goff
Journal:  Viruses       Date:  2016-03-30       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.